Market revenue in 2023 | USD 42.9 million |
Market revenue in 2030 | USD 61.8 million |
Growth rate | 5.4% (CAGR from 2023 to 2030) |
Largest segment | Crt-defibrillator |
Fastest growing segment | CRT-Pacemaker |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | CRT-Defibrillator, CRT-Pacemaker |
Key market players worldwide | Medtronic PLC, Abbott Laboratories, Boston Scientific Corp, BIOTRONIK, MicroPort Scientific Corp, LivaNova PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cardiac resynchronization therapy market will help companies and investors design strategic landscapes.
Crt-defibrillator was the largest segment with a revenue share of 55.71% in 2023. Horizon Databook has segmented the Argentina cardiac resynchronization therapy market based on crt-defibrillator, crt-pacemaker covering the revenue growth of each sub-segment from 2018 to 2030.
An increase in healthcare investments and government reforms are expected to drive the market in Argentina. In 2019, the Secretary of Health of Argentina established the National Health Technology Assessment Agency, with the support of Pan American Health Organization (PAHO), to deploy innovative ways of improving the healthcare sector.
Moreover, in early 2019, the government launched a national health plan under the Universal Health Coverage framework, to improve healthcare in the nation. These practices have increased growth opportunities for CRT manufacturing companies. Furthermore, a surge in CVD-related mortality is driving Argentina’s market.
According to the World Heart Federation, noncommunicable diseases account for 81% of deaths in the country, out of which, 31% are related to cardiac failure. In addition, an increase in predisposing factors has propelled the prevalence of CVDs. For instance, Argentina reported a 30% increase in patients with high cholesterol levels and a 53% increase in patients with hypertension, over the past 15 years.
Horizon Databook provides a detailed overview of country-level data and insights on the Argentina cardiac resynchronization therapy market , including forecasts for subscribers. This country databook contains high-level insights into Argentina cardiac resynchronization therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account